CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

open access:
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

 In conclusion, we demonstrated for the first time that the two CXCR3-binding chemokines CXCL9 and CXCL10 are independent predictors of an improved OS in HGSC. Furthermore, we identified the COX system as a suitable pharmacologic target to augment intratumoral chemokine concentrations. On the basis of our results, the addition of indomethacin, rather than celecoxib, to immunotherapies in future clinical trials should be explored, with the goal to improve their efficacy by enhancing the tumour-suppressive lymphocytic infiltration in ovarian cancer.